TerminatedPhase 2NCT02030405
Ixazomib (MLN9708) in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
Studying Acute erythroid leukemia
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Steven E. Coutre
- Principal Investigator
- Bruno de Medeiros, MDStanford University Hospitals and Clinics
- Intervention
- Ixazomib(drug)
- Enrollment
- 4 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2014 – 2015
Study locations (1)
- Stanford University Cancer Institute, Stanford, California, United States
Collaborators
National Cancer Institute (NCI)
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT02030405 on ClinicalTrials.govOther trials for Acute erythroid leukemia
Additional recruiting or active studies for the same condition.